Hernando del Portillo (President)
Mary Galinski (Vice-President)
Marcus Lacerda received his Medical Degree from the University of Brasília (1999), completed an Infectious Diseases Residency at the Tropical Medicine Foundation Dr. Heitor Vieira Dourado (FMT-HVD) (2002) and obtained his PhD degree in Tropical Medicine from the University of Brasília in partnership with the New York University (2007). He works as a physician at FMT-HVD and as a researcher at Instituto Leônidas & Maria Deane (FIOCRUZ-Amazonas). In addition, he collaborates with the Graduate Program on Tropical Medicine from the University of the Amazonas State, and is an adjunct professor at Kent State University. He is an expert in Infectious DIseases. Since 2007 he is the coordinator of the International Center for Clinical Malaria Research (CIPCliM), in Manaus (Brazilian Amazon), and is currently the Director of Research at FMT-HVD. He is a member of the Technical Advisory Committee of the Brazilian National Malaria Control Program, the Committee on Antimalarial Therapy from the Brazilian Ministry of Health, and serves also as an occasional consultant of the World Health Organization on P. vivax malaria. He is and has been actively involved in initiatives devoted to malaria elimination such as malERA, MESA and the Mesoamerica Initiative. He is also a member of the Expert Scientific Advisory Committee (ESAC) from Medicines for Malaria Venture (MMV) and WorldWide Antimalarial Resistance Network (WWARN). He is also an affiliate member of the Brazilian Academy of Sciences, and a level 1 researcher from CNPq. He is the President of the Brazilian Society of Tropical Medicine (2015 to 2017).
Institutional affiliation: Instituto Leônidas & Maria Deane (Fiocruz)/Tropical Medicine Foundation Dr Heitor Vieira Dourado, Brazil
Wuelton Monteiro earned his bachelor's degree in Pharmaceutical Sciences in 2004 and received his MSc degree in Biological Sciences in 2006. In 2011, he obtained his PhD degree in Tropical Diseases from the Amazonas State University at Manaus. In 2008, he moved to the Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), in Manaus, where he held positions as a Malaria Researcher and Vice-Coordinator of the International Center of Clinical Research in Malaria. Since 2011 he holds a joint appointment at FMT-HVD and the Amazonas State University as an Adjunt Professor of Epidemiology. He has experience in epidemiology of neglected parasitic diseases, focusing mainly in malaria. Recently, he has been dedicated more specifically to the study of the epidemiology and control of Plasmodium vivax malaria in the Amazon. His previous experiences in Plasmodium vivax malaria epidemiology and control include participation in projects such as Research program on Plasmodium vivax malaria (PI institution: Barcelona Institute for Global Health - ISGlobal; funded by Cellex Foundation; 2008-2011) and field coordination of the TransEPI Project in Manaus (funded by BMGF, 2011-2014). Currently, he is the PI of two projects funded by the Amazonas Research Support Agency (FAPEAM) and the National Counsel of Technological and Scientific Development (CNPq) aiming to test ivermectin effect on Latin America malaria vectors, and is a member of the Ivermectin Research for Malaria Elimination Network. Moreover, he is coordinating all the field work of an Amazonian survey to estimate G6PD deficiency in the region.
Institutional Affiliation: University of the Amazonas State/Tropical Medicine Foundation Dr Heitor Vieira Dourado, Brazil
Stefanie Lopes is a Researcher in Public Health at Institute Leônidas e Maria Deane - Fiocruz Amazônia located in Manaus (Amazonas State, Brazil). She has graduated in Biological Sciences from University of Campinas, Brazil (2002), where she obtained MSc (2008) and PhD (2012) degrees in Genetics and Molecular Biology. Her main research area is the biology of Plasmodium vivax, focusing on the comprehension of the biological meaning of cytoadhesive phenotypes of this Plasmodium specie. Her group is presently investigating P. vivax gametocyte cytoadhesive abilities and its role on mosquito’s infection. In addition, the group is also attempting to develop a platform to investigate drugs with action in asexual and sexual P. vivax blood stages.
Institutional affiliation: Instituto Leônidas & Maria Deane (Fiocruz), Brazil
Hernando del Portillo studied at the University of Georgia where he received his PhD in 1985 followed by two WHO-postdoctoral trainings at the New York University Medical Centre and the Institut Pasteur where he specialized in molecular biology of malaria. Next, he consolidated an interdisciplinary and multi-Centric malaria research group at the University of Sao Paulo, Brazil. In 1990, he did a sabbatical year at the Centre for Molecular Biology (ZMBH), University of Heidelberg. In 2007, he joined the Barcelona Institute for Global Health, and this year co-joined the Institut d’Investigació Germans Trias i Pujol. Cornerstones of this research activity are the discovery of the largest multigene virulent family of human malaria parasites involved in spleen immune evasion and the discovery that reticulocyte-derived exosomes from infections act as intercellular communicators and can be used as a novel vaccine and platform against malaria. His main research area is the biology of Plasmodium vivax, a neglected human malaria parasite responsible for millions of yearly clinical cases. His group is presently looking for mechanistic insights of the role of reticulocyte-derived exosomes, nanovesicles of endocytic origin, in signalling the spleen and the bone marrow to unveil molecular basis of anaemia and splenomegaly and to use this information in developing novel control strategies. In addition, the group is exploring the use of exosomes as novel vaccines and biomarkers in the context of elimination. Last, the group is also attempting to develop a continuous in vitro culture system for blood stages of this malaria species, a major technological key-gap to advance studies of this neglected human malaria.
Institutional affiliation: ICREA Research Professor at Barcelona Institute for Global Health (ISGlobal) & Institut d’Investigació Germans Trias i Pujol (IGTP), Spain
Mary Galinski's laboratory, located at the Emory Vaccine Center at the Yerkes National Primate Research Center, develops projects addressing molecular and cell biology, immunology, genetics, pathogenesis and epidemiology questions that are pertinent to understanding the complexities of MALARIA and the hurdles faced in developing and implementing effective malaria vaccines and drugs. The team is focused on advancing basic, pre-clinical and clinical research goals, while also making a difference immediately in the lives of people living in malaria endemic countries. In line with Emory University’s strategic plan and goals pertinent to internationalization, global health and developing nations, her research program has become the springboard for developing Emory’s International Center for Malaria Research, Education and Development (ICMRED).
Institutional affiliation: Emory University School of Medicine, USA
Fábio Costa: PhD and MSc in Microbiology, Immunology, and Parasitology from the Federal University of São Paulo, and BSc degree in Biological Sciences from the University of Brasília. Dr. Costa is associate Professor of Parasitology at University of Campinas (UNICAMP) located in Campinas (São Paulo State, Brazil). As a malaria researcher at UNICAMP, Dr. Costa is an expert in basic research, focusing on the immunopathological aspects of Plasmodium spp. infections and on the discovery and development of experimental drugs and vaccines. Dr. Costa also works as academic Editor for PLoSOne and Frontiers in Immunology Journals. Dr. Costa graduated in Biological Sciences at University of Brasilia in 1994. He obtained his Masters’ and PhD degree at Federal University of São Paulo in 1998 and 2001, respectively. From 2001 to 2003, he attended to Université de La Méditerranée/Institut Pasteur (France) as a post-doctoral fellow, working on human and experimental malaria.
Institutional affiliation: Institute of Biology, University of Campinas, Brazil
Ivo Müeller: PhD, born and educated in Switzerland. He holds an MSc in Botany & Population Biology from University of Basel, an MSc in Statistics from University of Neuchatel, and a PhD in Epidemiology from the Swiss Tropical Institute. He held a number of positions at the Papua New Guinea Institute of Medical Research, including Malaria Epidemiologist (2002-04), Head Vector Borne Disease Unit (2005-07), Chief Scientist (2008), and Deputy Director for Science (2009-10). Since 2011, he has been leading a laboratory at the Walter & Eliza Hall Institute with a joint appointment with ISGlobal and more recently the Institut Pasteur in Paris. His lab atISGlobal and the Walter & Eliza Hall Institute is conducting population-based malaria studies that are both scientifically excellent and locally relevant for the control and eventual elimination of malaria by bridging from basic Plasmodium biology to clinical development of new interventions to control and eventually eliminate malaria. To that effect the research is focused around three main themes: 1) the comparative biology of P. falciparum and P. vivax host-parasite interactions; 2) the (clinical) epidemiology and intervention research in Papua New Guinea and the Americas; and 3)evaluation of the impact of intensified malaria control programs on malaria burden and host-vector-parasite interaction.
Institutional affiliation: Walter & Eliza Hall Institute, Australia/Institut Pasteur, France
Jane Carlton is a biologist at New York University whose research centers on the genomics of two groups of single-celled parasites: those which cause malaria (the genus Plasmodium). Dr. Carlton records and categorizes changes in the malaria parasite’s genes, with a view toward detecting drug resistance in its earliest stages, finding new vulnerabilities in the parasite’s genome that can be exploited to control it, and providing basic understanding of the parasite’s complex biology. As Director of NYU’s Center for Genomics and Systems Biology, Carlton is examining the genomes of dozens of malaria isolates at a time. Recently Dr. Carlton and her colleagues sequenced ~200 genomes from both a human malaria species (P. vivax), as well as several from a closely related monkey malaria parasite (P. cynomolgi), producing a more detailed picture of malaria parasite evolution and uncovering a surprising amount of genetic variation. Dr. Carlton collaborates with scientists in India to develop new control strategies for the disease there. As Program Director of a seven-year NIH International Center of Excellence in Malaria Research based jointly in India and at NYU, she is leading the first pan-Indian genomic survey of malaria parasite strains, as well as undertaking research on how malaria is transmitted, and manifests itself in different ecologies and communities in India.
Institutional affiliation: New York University’s Center for Genomics and Systems Biology, USA
Jetsumon Prachumsri is the Director of Mahidol Vivax Research Unit (MVRU), Faculty of Tropical Medicine, Mahidol University established in March 2011. Dr. Jetsumon Sattabongkot Prachumsri started her malaria research in 1985 when she was with the US Army Medical Component, Armed Forces Research Institute of Medeical Science (USAMC-AFRIMS), Bangkok which is an oversea laboratory of Walter Reed Army Institute of Research (WRAIR), Bethesda, USA. More than 30 years of experience in malaria research performed in Thailand and other countries in Asia and with her excellent research staff, many of whom have been working on malaria research for more than ten years, the MVRU has already engaged in many research projects in collaboration with many institutes all over the globe. Her unit has unique expertise that advance research in Plasmodium vivax and transmission stages of human malaria including both, but not limited to, P. falciparum and P. vivax. She has been interested and has focused her research on malaria epidemiology, biology, diagnosis and surveillance, and transmission of the vector borne diseases in endemic population.
Institutional affiliation: Mahidol Vivax Research Unit (MVRU), Thailand
John Adams joined the University of South Florida College of Public Health Global Health Infectious Diseases Research program in June 2007 and previously was at the University of Notre Dame for 16 years. He was trained in basic parasitology (BA 1978, Hendrix College; PhD 1985, University of Illinois; 1986-87, Postdoctoral Fellow, University of Queensland) and in molecular approaches to malaria at National Institutes of Health, 1987-1991. His research program studies malaria parasite biology with the expectation that a better understanding of Plasmodium biology will enable developing better ways to control malaria through vaccines, drugs and other prevention strategies.
Institutional affiliation: University of South Florida, USA
Kevin Baird earned a B.Sc. in Microbiology and a M.Sc. in Biochemistry from University of Maryland in 1980 and 1983, and a Ph.D. in Medical Zoology from Tulane University School of Public Health and Tropical Medicine in 1994. He began working on malaria at the Division of Experimental Therapeutics at Walter Reed Army Institute of Research in 1981. He was commissioned into the US Navy Medical Service Corps in 1984 and over 22 years of active duty served four permanent assignments at US Naval Medical Research Unit #2 in Jakarta, Indonesia, along with assignments to Philippines, Ghana, Peru and Washington, DC. Since 2007 Prof. Baird has directed the Eijkman-Oxford Clinical Research Unit in Jakarta on behalf of Oxford University, where he is Professor of Malariology, Nuffield Department of Medicine. An internationally acknowledged expert on Plasmodium vivax malaria, he serves on several committees, working groups, and review groups at the World Health Organization’s Global Malaria Program. Prof. Baird’s clinical research unit conducts clinical trials of anti-infective agents, especially hypnozoitocides, engaging pharmacokinetic and pharmacogenetic studies, along with experimental diagnostics for malaria and G6PD deficiency. Studies of the epidemiology of vivax malaria/G6PD deficiency/CYP2D6 polymorphisms in Indonesia support all of these studies.
Institutional affiliation: Eijkman-Oxford Clinical Research Unit, Indonesia
Marcelo Ferreira is a medical parasitologist with over 20-year experience in field-oriented and laboratory malaria research, mostly in Amazonian Brazil. He graduated in Medicine from the University of São Paulo, Brazil (1988), where he was trained in Internal Medicine (1999-2004) and obtained his MSc (1993) and PhD (1997) degrees. Further research training was obtained in Japan (Nagoya University, 1995-97) and the United States (Harvard University, 2005-06). His overall research goal is to provide scientific evidence that can be translated into effective public health interventions for malaria control in Amazonia. He teaches medical parasitology at the University of São Paulo and currently serves as a member of the Technical Advisory Committee on Malaria of the Pan-American Health Organization.
Institutional affiliation: University of São Paulo, Brazil
Penny Grewal-Daumerie is a Senior Advisor/Consultant for Medicines for Malaria Venture (MMV) in Geneva; prior to this, she was Director of Global Access at MMV for nearly a decade. Her work is centered around facilitating patient access to treatment, with a special focus on supporting introduction of an improved radical cure for P. vivax malaria. She works closely with the WHO, National Malaria Control Programmes, pharma partners and stakeholders to ensure the acceptability, affordability and availability of new medicines.In India, Penny collaborates closely with the National Institute of Malaria Research and the National Vector Borne Disease Control Programme to improve access to treatment, including P. vivax radical cure, within the framework of the MMV-co-sponsored Comprehensive Case Management Programme in Odisha. Prior to her work with MMV, Penny was the head of the health sector at the Novartis Foundation, spearheading the global drug donation programme of Multiple Drug Therapy for leprosy in collaboration with the WHO. She has a Master’s of Business Administration (MBA) from INSEAD, Fontainebleau, France and B.A. Hons (Economics), Bombay University, India.
Institutional affiliation: Medicines for Malaria Venture, Switzerland
Quique Bassat is a pediatrician, with special interest in infectious disease epidemiology and public health, Dr. Bassat has attempted to combine his clinical work with biomedical research in those diseases that most affect the poor and vulnerable. Originally based in Manhiça, Mozambique, he worked there as a pediatrician and a clinical researcher, participating in different clinical trials related to malaria prevention and treatment, such as the different RTS,S malaria candidate vaccine clinical trials (infant and older children studies). He also led the Manhiça part of different phase III multicentre antimalarial drug studies that were decisive for the clinical development of new antimalarial drugs (dihydroartemisinin-piperaquine; dispersable artemether-lumefantrine). He was also particularly interested in the study of the burden, trends and characterization of malaria in children admitted to hospital, and the overlapping symptomatology between malaria and other common infectious diseases. While his work was initially focused in P. falciparum malaria and children, he has widened his scope of interest to the study of P. vivax. In recent years, in addition to the ongoing work in Mozambique, he has become involved in the implementation of various P. vivax related studies in countries such as Brazil, India or Papua New Guinea, aiming to describe in greater depth the epidemiology and clinical manifestations related to this species. Such work has included the first fully-characterized large series of P. vivax severe cases collected from two very distinct countries (Brazilian Amazon and India’s Rajasthan) following an identical protocol, and the first series of P. vivax associated deaths fully studied through complete autopsy.
Institutional affiliation: ICREA & Profesor at the Institut de Salut Global de Barcelona (ISGlobal), Spain
Ric Price: Infectious diseases and general physician on the staff at the Royal Darwin Hospital. His translational research program focuses on improving the diagnosis and management of multidrug resistant Plasmodium falciparum and P. vivax infections through a research agenda that spans clinical studies, epidemiology, health economics, pathophysiology, immunology, in vitro studies and molecular biology. He is currently leading multicentred clinical trials in more than seven malaria endemic countries to optimise the use of primaquine for the radical cure of vivax malaria. Professor Price chairs the clinical module of the World Wide Antimalarial Resistance Network (WWARN) and the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
Institutional affiliation: Menzies School of Health Research, Australia/University of Oxford, UK
Socrates Herrera: Extensive experience and broad background on malaria immunology, vaccinology and more recently epidemiological clinical studies built up over more than 25 years of research, first as director (PD) of the Malaria Vaccine and Drugs Development Center, afterwards as the program director of a Tropical Medicine Research Center (TMRC) sponsored by NIAID/NIH, and more recently as PD of the Latin American Center for Malaria Research (CLAIM). The purpose of the ongoing CLAIM is to generate knowledge and provide technical and scientific support to governments of Latin America (LA), required to accelerate the development of malaria vaccines that are expected to significantly strengthen the current malaria control measures and facilitate malaria control/elimination. CLAIM's goal is to design and conduct multidisciplinary research to strengthen our understanding of malaria immune responses in individuals exposed to malaria to be developed mainly in Colombia, were CLAIM is focusing activities in four of the most endemic areas of the country (Quibdo, Tierralta, Tumaco and Buenaventura) that count with the support from local authorities and malaria stakeholders to facilitate the success of the renewal program.
Institutional affiliation: Institute of Immunology, Colombia
Carmen Fernandez-Becerra received a Ph.D. in Biological Sciences from the University of Granada. Later, she moved to Brazil (University of Sao Paulo), where she did her first post-doctotal training, working on biological aspects of Plasmodium vivax. In 1998, she joined the ZMBH (Heidelberg) where she did her second postdoctoral stay working with Toxoplasma gondii. In 2000, she moved back to the University of Sao Paulo as a Research Associated Fellow to continue her studies on P. vivax. In 2007, she joined ISGlobal's research centre as Assistant Research Professor, since then, she has been working in the program of malaria.
Institutional affiliation: Barcelona Institute for Global Health (ISGlobal) & Institut d’Investigació Germans Trias i Pujol (IGTP), Spain
Rosalind Howes is a post-doctoral epidemiologist based with the Malaria Atlas Project (MAP) at the University of Oxford. She completed her PhD studies with the MAP group, focussing on the global epidemiology of human red blood cell polymorphisms closely associated with Plasmodium vivax: the Duffy blood group and G6PD deficiency. She now splits her time between Oxford and Madagascar where she is a field epidemiologist investigating interactions between P. vivax and Duffy negativity (Project PI: Peter Zimmerman, Case Western Reserve University, USA). Through the MAP group, she is also involved with ongoing efforts to refine estimates of the global clinical burden of P. vivax malaria.
Institutional affiliation: University of Oxford, United Kingdom